An observational study in Migraine, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.
Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 34th largest by planned enrollment of the 42 observational ones that give a count, is one of 19 that started in 2023, is one of 42 observational ones, reaches primary completion later than 29 of the 46 other live ones, and was the 70th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 18–75 · Healthy volunteers
University of Roma La Sapienza · Sites in Italy
Ages 18–65
Istituto Auxologico Italiano · Sites in Italy
Ages 18–70
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18–65
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 19 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 315 across the 73 interventional studies, 108 across the 42 observational. Of the 58 that completed or were terminated, 26 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 115 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 3 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Migraine Disorders with a site in Italy that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 15 to your calendar (.ics) → With an account.
Among the 115 studies in Migraine Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to investigate the role of the glymphatic system in the initiation of migraine attacks, using non-invasive magnetic resonance imaging techniques and a validated model of migraine induction by nitroglycerin administration. Secondarily, the relationship between the function of the glymphatic system during nitroglycerin-induced migraine attacks and sleep architecture and plasma levels of migraine-involved neuropeptides will be investigated.
Patients with a diagnosis of episodic migraine without aura, by the standard ICHD diagnostic criteria, will be prospectively recruited. Patients will be allowed to take only one migraine preventive treatment at a stable dose during the study. Healthy controls suffering from any headaches with the exception of infrequent tension-type headache will be excluded from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients:
For both patients and healthy controls:
Exclusion criteria
For patients:
For healthy controls:
For both patients and healthy controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnosis of migraine, by the ICHD-3 criteria. Age between 18 and 60 years. Female and males. Right-handed
Drug: Nitroglycerin 0.3 MG · Diagnostic Test: MRI · Diagnostic Test: Blood sampling · Device: Sleep profiler
Age between 18 and 60 years. Female and males. Right-handed
Drug: Nitroglycerin 0.3 MG · Diagnostic Test: MRI · Diagnostic Test: Blood sampling · Device: Sleep profiler
Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
Change from baseline glymphatic function after nitroglycerin administration
The DTI-ALPS index will be quantified before and after nitroglycerin administration as an indirect measure of the glymphatic function
Time frame: Up to 8 hours
Change from baseline plasma levels of neuropeptides after nitroglycerin administration
ELISA kits will be used to measure the plasma level of neuropeptides involved in migraine pathophysiology before and after nitroglycerin administration
Time frame: Up to 8 hours
Change from baseline sleep architecture after nitroglycerin administration
Sleep Architecture will be studied through the Sleep Profiler before and after nitroglycerin administration
Time frame: Up to 8 hours
Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 47 months is above that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jun 2025 → Mar 2027 and completion Apr 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.